Actively Recruiting
CAR-T Following ASCT for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (R/R B-NHL) With High-Risk Prognostic Factors
Led by Ruijin Hospital · Updated on 2026-01-06
16
Participants Needed
1
Research Sites
154 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Clinical trial for the safety and efficacy of CD19 CAR-T following autologous hematopoietic stem cell transplantation (ASCT) for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (R/R B-NHL) with High-Risk Prognostic Factors
CONDITIONS
Official Title
CAR-T Following ASCT for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (R/R B-NHL) With High-Risk Prognostic Factors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically confirmed B-cell non-Hodgkin's lymphoma including diffuse large B-cell lymphoma, high-grade B-cell lymphoma, transformed lymphoma, primary mediastinal large B-cell lymphoma, or follicular lymphoma
- Relapsed or refractory disease after anti-CD20 monoclonal antibody and anthracycline chemotherapy with specific criteria for progression or response
- Presence of at least one high-risk factor: extranodal involvement, bulky mass 5 cm or larger, or TP53 gene alterations
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
- Eligible for high-dose chemotherapy and autologous stem cell transplant and planned for sequential CAR-T treatment
- Adequate kidney and liver function with specified laboratory values
- Cardiac ejection fraction of 40% or higher
- Baseline oxygen saturation above 95% on room air
- Life expectancy of 3 months or more
You will not qualify if you...
- Previous autologous or allogeneic stem cell transplantation
- Active hepatitis B or C infection with abnormal viral DNA levels
- Uncontrolled infections, cardiovascular or cerebrovascular disease, blood clotting disorders, or connective tissue diseases
- History of HIV infection
- Prior CD19-targeted chimeric antigen receptor cellular immunotherapy
- Pregnancy or breastfeeding
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, China
Actively Recruiting
Research Team
W
Weili Zhao
CONTACT
L
Li Wang
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here